About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2006 (2006), Article ID 74539, 5 pages
http://dx.doi.org/10.1155/JBB/2006/74539
Review Article

Tau Phosphorylation, Aggregation, and Cell Toxicity

Centro de Biología Molecular “Severo Ochoa”, Facultad de Ciencias, Universidad Autónoma de Madrid, Campus de Cantoblanco, Madrid 28049, Spain

Received 28 November 2005; Revised 16 December 2005; Accepted 3 January 2006

Copyright © 2006 J. Avila et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S B Prusiner, “Shattuck lecture—neurodegenerative diseases and prions,” The New England Journal of Medicine, vol. 344, no. 20, pp. 1516–1526, 2001. View at Publisher · View at Google Scholar · View at PubMed
  2. M Sadqi, F Hernández, U Pan, et al., “Alpha-helix structure in Alzheimer's disease aggregates of tau-protein,” Biochemistry, vol. 41, no. 22, pp. 7150–7155, 2002. View at Publisher · View at Google Scholar · View at PubMed
  3. M Arrasate, S Mitra, E S Schweitzer, M R Segal, and S Finkbeiner, “Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death,” Nature, vol. 431, no. 7010, pp. 805–810, 2004. View at Publisher · View at Google Scholar · View at PubMed
  4. V T Marchesi, “An alternative interpretation of the amyloid Abeta hypothesis with regard to the pathogenesis of Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 26, pp. 9093–9098, 2005. View at Publisher · View at Google Scholar · View at PubMed
  5. N F Bence, R M Sampat, and R R Kopito, “Impairment of the ubiquitin-proteasome system by protein aggregation,” Science, vol. 292, no. 5521, pp. 1552–1555, 2001. View at Publisher · View at Google Scholar · View at PubMed
  6. G Merlini and V Bellotti, “Molecular mechanisms of amyloidosis,” The New England Journal of Medicine, vol. 349, no. 6, pp. 583–596, 2003. View at Publisher · View at Google Scholar · View at PubMed
  7. C A Ross and M A Poirier, “Protein aggregation and neurodegenerative disease,” Nature Medicine, vol. 10, no. suppl, pp. S10–S17, 2004. View at Publisher · View at Google Scholar · View at PubMed
  8. J Avila, J J Lucas, M Pérez, and F Hernández, “Role of tau protein in both physiological and pathological conditions,” Physiological Reviews, vol. 84, no. 2, pp. 361–384, 2004. View at Publisher · View at Google Scholar · View at PubMed
  9. R A Crowther, O F Olesen, R Jakes, and M Goedert, “The microtubule binding repeats of tau protein assemble into filaments like those found in Alzheimer's disease,” FEBS Letters, vol. 309, no. 2, pp. 199–202, 1992. View at Publisher · View at Google Scholar · View at PubMed
  10. E Montejo de Garcini, L Serrano, and J Avila, “Self assembly of microtubule associated protein tau into filaments resembling those found in Alzheimer disease,” Biochemical and Biophysical Research Communications, vol. 141, no. 2, pp. 790–796, 1986. View at Publisher · View at Google Scholar · View at PubMed
  11. M Pérez, J M Valpuesta, M Medina, E Montejo de Garcini, and J Avila, “Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction,” Journal of Neurochemistry, vol. 67, no. 3, pp. 1183–1190, 1996. View at PubMed
  12. H Wille, G Drewes, J Biernat, E M Mandelkow, and E Mandelkow, “Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro,” The Journal of Cell Biology, vol. 118, no. 3, pp. 573–584, 1992. View at Publisher · View at Google Scholar · View at PubMed
  13. I Santa-María, F Hernández, M A Smith, G Perry, J Avila, and F J Moreno, “Neurotoxic dopamine quinone facilitates the assembly of tau into fibrillar polymers,” Molecular and Cellular Biochemistry, vol. 278, no. 1-2, pp. 203–212, 2005. View at PubMed
  14. W M van Roon-Mom, S J Reid, R L Faull, and R G Snell, “TATA-binding protein in neurodegenerative disease,” Neuroscience, vol. 133, no. 4, pp. 863–872, 2005. View at Publisher · View at Google Scholar · View at PubMed
  15. D C David, R Layfield, L Serpell, Y Narain, M Goedert, and M G Spillantini, “Proteasomal degradation of tau protein,” Journal of Neurochemistry, vol. 83, no. 1, pp. 176–185, 2002. View at Publisher · View at Google Scholar · View at PubMed
  16. N Sahara, M Murayama, T Mizoroki, et al., “In vivo evidence of CHIP up-regulation attenuating tau aggregation,” Journal of Neurochemistry, vol. 94, no. 5, pp. 1254–1263, 2005. View at Publisher · View at Google Scholar · View at PubMed
  17. G V Johnson, R S Jope, and L I Binder, “Proteolysis of tau by calpain,” Biochemical and Biophysical Research Communications, vol. 163, no. 3, pp. 1505–1511, 1989. View at Publisher · View at Google Scholar · View at PubMed
  18. H Shimura, D Schwartz, S P Gygi, and K S Kosik, “CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival,” The Journal of Biological Chemistry, vol. 279, no. 6, pp. 4869–4876, 2004. View at Publisher · View at Google Scholar · View at PubMed
  19. P J Kahle and C Haass, “How does parkin ligate ubiquitin to Parkinson's disease?,” EMBO Reports, vol. 5, no. 7, pp. 681–685, 2004. View at Publisher · View at Google Scholar · View at PubMed
  20. M S Gentry, C A Worby, and J E Dixon, “Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 24, pp. 8501–8506, 2005. View at Publisher · View at Google Scholar · View at PubMed
  21. T C Gamblin, R W Berry, and L I Binder, “Tau polymerization: role of the amino terminus,” Biochemistry, vol. 42, no. 7, pp. 2252–2257, 2003. View at Publisher · View at Google Scholar · View at PubMed
  22. T C Gamblin, R W Berry, and L I Binder, “Modeling tau polymerization in vitro: a review and synthesis,” Biochemistry, vol. 42, no. 51, pp. 15009–15017, 2003. View at Publisher · View at Google Scholar · View at PubMed
  23. T C Gamblin, M E King, H Dawson, et al., “In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants,” Biochemistry, vol. 39, no. 20, pp. 6136–6144, 2000. View at Publisher · View at Google Scholar · View at PubMed
  24. T C Gamblin, M E King, J Kuret, R W Berry, and L I Binder, “Oxidative regulation of fatty acid-induced tau polymerization,” Biochemistry, vol. 39, no. 46, pp. 14203–14210, 2000. View at Publisher · View at Google Scholar · View at PubMed
  25. I Grundke-Iqbal, K Iqbal, Y C Tung, M Quinlan, H M Wisniewski, and L I Binder, “Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 13, pp. 4913–4917, 1986. View at Publisher · View at Google Scholar · View at PubMed
  26. M D Ledesma, P Bonay, C Colaço, and J Avila, “Analysis of microtubule-associated protein tau glycation in paired helical filaments,” The Journal of Biological Chemistry, vol. 269, no. 34, pp. 21614–21619, 1994. View at PubMed
  27. C M Wischik, R YK Lai, and C R Harrington, “Modelling prion-like processing of tau protein in Alzheimer's disease for pharmaceutical development,” in Brain Microtubule Associated Proteins: Modification in Disease, J Avila, R Brandt, and K S Kosik, Eds., pp. 185–241, Harwood Academic, Chur, Switzerland, 1997.
  28. M Pérez, M Arrasate, E Montejo de Garcini, V Munoz, and J Avila, “In vitro assembly of tau protein: mapping the regions involved in filament formation,” Biochemistry, vol. 40, no. 20, pp. 5983–5991, 2001. View at PubMed
  29. I Santa-María, F Hernández, C P Martin, J Avila, and F J Moreno, “Quinones facilitate the self-assembly of the phosphorylated tubulin binding region of tau into fibrillar polymers,” Biochemistry, vol. 43, no. 10, pp. 2888–2897, 2004. View at PubMed
  30. W Noble, E Planel, C Zehr, et al., “Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 19, pp. 6990–6995, 2005. View at Publisher · View at Google Scholar · View at PubMed
  31. M Pérez, F Hernández, F Lim, J Diaz-Nido, and J Avila, “Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model,” Journal of Alzheimer's Disease, vol. 5, no. 4, pp. 301–308, 2003. View at PubMed
  32. I E Vega, L Cui, J A Propst, M L Hutton, G Lee, and S H Yen, “Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates,” Brain Research. Molecular Brain Research, vol. 138, no. 2, pp. 135–144, 2005. View at Publisher · View at Google Scholar · View at PubMed
  33. K Duff and E Planel, “Untangling memory deficits,” Nature Medicine, vol. 11, no. 8, pp. 826–827, 2005. View at Publisher · View at Google Scholar · View at PubMed
  34. F Lim, F Hernández, J J Lucas, P Gomez-Ramos, M A Moran, and J Avila, “FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain,” Molecular and Cellular Neuroscience, vol. 18, no. 6, pp. 702–714, 2001. View at Publisher · View at Google Scholar · View at PubMed
  35. F Hernández, R Cuadros, and J Avila, “Zeta 14-3-3 protein favours the formation of human tau fibrillar polymers,” Neuroscience Letters, vol. 357, no. 2, pp. 143–146, 2004. View at PubMed
  36. M A Lovell and W R Markesbery, “Ectopic expression of Musashi-1 in Alzheimer disease and Pick disease,” Journal of Neuropathology and Experimental Neurology, vol. 64, no. 8, pp. 675–680, 2005. View at PubMed
  37. P J Lu, G Wulf, X Z Zhou, P Davies, and K P Lu, “The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein,” Nature, vol. 399, no. 6738, pp. 784–788, 1999. View at Publisher · View at Google Scholar · View at PubMed
  38. M Poli, L B Gatta, R Dominici, et al., “DNA sequence variations in the prolyl isomerase Pin1 gene and Alzheimer's disease,” Neuroscience Letters, vol. 389, no. 2, pp. 66–70, 2005. View at Publisher · View at Google Scholar · View at PubMed
  39. V M Lee, M Goedert, and J Q Trojanowski, “Neurodegenerative tauopathies,” Annual Review of Neuroscience, vol. 24, pp. 1121–1159, 2001. View at Publisher · View at Google Scholar · View at PubMed
  40. S C Feinstein and L Wilson, “Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death,” Biochimica et Biophysica Acta, vol. 1739, no. 2-3, pp. 268–279, 2005. View at PubMed
  41. M Goedert, S Satumtira, R Jakes, et al., “Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations,” Journal of Neurochemistry, vol. 75, no. 5, pp. 2155–2162, 2000. View at Publisher · View at Google Scholar · View at PubMed
  42. R Brandt, M Hundelt, and N Shahani, “Tau alteration and neuronal degeneration in tauopathies: mechanisms and models,” Biochimica et Biophysica Acta, vol. 1739, no. 2-3, pp. 331–354, 2005. View at PubMed
  43. C Andorfer, C M Acker, Y Kress, P R Hof, K Duff, and P Davies, “Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms,” The Journal of Neuroscience, vol. 25, no. 22, pp. 5446–5454, 2005. View at Publisher · View at Google Scholar · View at PubMed
  44. H G Lee, G Perry, P I Moreira, et al., “Tau phosphorylation in Alzheimer's disease: pathogen or protector?,” Trends in Molecular Medicine, vol. 11, no. 4, pp. 164–169, 2005. View at Publisher · View at Google Scholar · View at PubMed
  45. P V Arriagada, J H Growdon, E T Hedley-Whyte, and B T Hyman, “Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease,” Neurology, vol. 42, no. 3 pt 1, pp. 631–639, 1992. View at PubMed
  46. H Braak and E Braak, “Neuropathological stageing of Alzheimer-related changes,” Acta Neuropathologica (Berl), vol. 82, no. 4, pp. 239–259, 1991. View at Publisher · View at Google Scholar · View at PubMed
  47. A Alzheimer, “Über eigenartige Krankheitsfälle des späteren Alters,” Zeitschrift für die gesamte Neurologie und Psychiatrie, vol. 4, pp. 356–385, 1911.
  48. P Cras, M A Smith, P L Richey, S L Siedlak, P Mulvihill, and G Perry, “Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease,” Acta Neuropathologica (Berl), vol. 89, no. 4, pp. 291–295, 1995. View at PubMed
  49. Y Fukutani, K Kobayashi, I Nakamura, K Watanabe, K Isaki, and N J Cairns, “Neurons, intracellular and extracellular neurofibrillary tangles in subdivisions of the hippocampal cortex in normal ageing and Alzheimer's disease,” Neuroscience Letters, vol. 200, no. 1, pp. 57–60, 1995. View at Publisher · View at Google Scholar · View at PubMed
  50. W Bondareff, C Q Mountjoy, M Roth, and D L Hauser, “Neurofibrillary degeneration and neuronal loss in Alzheimer's disease,” Neurobiology of Aging, vol. 10, no. 6, pp. 709–715, 1989. View at Publisher · View at Google Scholar · View at PubMed
  51. M Goedert, “Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies,” Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, vol. 354, no. 1386, pp. 1101–1118, 1999. View at Publisher · View at Google Scholar · View at PubMed
  52. R Morsch, W Simon, and P D Coleman, “Neurons may live for decades with neurofibrillary tangles,” Journal of Neuropathology and Experimental Neurology, vol. 58, no. 2, pp. 188–197, 1999. View at PubMed
  53. K Santacruz, J Lewis, T Spires, et al., “Tau suppression in a neurodegenerative mouse model improves memory function,” Science, vol. 309, no. 5733, pp. 476–481, 2005. View at Publisher · View at Google Scholar · View at PubMed
  54. B Caughey and P T Lansbury, “Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders,” Annual Review of Neuroscience, vol. 26, pp. 267–298, 2003. View at Publisher · View at Google Scholar · View at PubMed
  55. T D Bird, D Nochlin, P Poorkaj, et al., “A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L),” Brain, vol. 122, no. pt 4, pp. 741–756, 1999. View at Publisher · View at Google Scholar · View at PubMed
  56. A Delacourte, J P David, N Sergeant, et al., “The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease,” Neurology, vol. 52, no. 6, pp. 1158–1165, 1999. View at PubMed
  57. T Gomez-Isla, R Hollister, H West, et al., “Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease,” Annals of Neurology, vol. 41, no. 1, pp. 17–24, 1997. View at Publisher · View at Google Scholar · View at PubMed